Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q1 2023
Holdings as of Mar 31, 2023, filed May 15, 2023. Long positions only; changes compare share counts with Q4 2022.
- Positions
- 52
- +17 vs. Q4 2022
- Portfolio value
- $264.3M
- +$30.1M (+12.9%) vs. Q4 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| VNDAVanda Pharmaceuticals Inc. | COM | 12,500 | $85.0K | <0.1% | +12,500 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 25,000 | $415.0K | 0.2% | +25,000 | New | History |
| IMGNImmunoGen, Inc. | COM | 124,977 | $480.0K | 0.2% | +124,977 | New | History |
| KYNBKyntra Bio, Inc. | COM | 26,500 | $494.0K | 0.2% | +26,500 | New | History |
| KZRKezar Life Sciences, Inc. | COM | 175,000 | $548.0K | 0.2% | −164,907−48.5% | Reduced | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 27,578 | $710.0K | 0.3% | +27,578 | New | History |
| XFORX4 Pharmaceuticals, Inc | COM | 850,000 | $740.0K | 0.3% | −150,000−15.0% | Reduced | History |
| GERNGeron Corp | COM | 450,000 | $977.0K | 0.4% | +450,000 | New | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 80,000 | $1.01M | 0.4% | 00.0% | Unchanged | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 150,000 | $1.09M | 0.4% | +60,000+66.7% | Added | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 350,000 | $1.32M | 0.5% | +350,000 | New | History |
| RCUSArcus Biosciences, Inc. | COM | 75,000 | $1.37M | 0.5% | +75,000 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 200,000 | $1.54M | 0.6% | +200,000 | New | History |
| RXDXPrometheus Biosciences, Inc. | COM | 15,000 | $1.61M | 0.6% | +5,104+51.6% | Added | History |
| Avidity Biosciences, Inc.05370A108 | COM | 125,000 | $1.92M | 0.7% | +25,000+25.0% | Added | – |
| IRONDisc Medicine, Inc. | COM | 100,000 | $2.12M | 0.8% | +100,000 | New | History |
| Rain Oncology Inc.75082Q105 | COM | 250,000 | $2.19M | 0.8% | +250,000 | New | – |
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 250,000 | $2.23M | 0.8% | +250,000 | New | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 275,000 | $2.29M | 0.9% | +50,000+22.2% | Added | History |
| ETNB89bio, Inc. | COM | 200,000 | $3.05M | 1.2% | +200,000 | New | History |
| KRTXKaruna Therapeutics, Inc. | COM | 17,500 | $3.18M | 1.2% | −22,500−56.3% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 425,000 | $3.44M | 1.3% | +425,000 | New | History |
| BMEABiomea Fusion, Inc. | COM | 120,000 | $3.72M | 1.4% | +120,000 | New | History |
| JBIOJade Biosciences, Inc. | COM | 200,000 | $4.03M | 1.5% | +65,000+48.1% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 195,000 | $4.17M | 1.6% | +195,000 | New | History |
| ISEEIVERIC bio, Inc. | COM | 175,000 | $4.26M | 1.6% | −275,000−61.1% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 175,000 | $4.45M | 1.7% | +10,000+6.1% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 225,000 | $5.17M | 2.0% | +225,000 | New | History |
| MRTXMirati Therapeutics, Inc. | COM | 140,000 | $5.21M | 2.0% | −60,000−30.0% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 475,000 | $5.27M | 2.0% | +475,000 | New | History |
| INCYIncyte Corp | COM | 75,000 | $5.42M | 2.1% | +75,000 | New | History |
| COGTCogent Biosciences, Inc. | COM | 550,000 | $5.93M | 2.2% | −250,000−31.3% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 450,000 | $5.99M | 2.3% | 00.0% | Unchanged | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 1,000,000 | $6.11M | 2.3% | −300,000−23.1% | Reduced | History |
| RETAReata Pharmaceuticals Inc | CL A | 70,000 | $6.36M | 2.4% | −430,000−86.0% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 325,000 | $6.86M | 2.6% | +175,000+116.7% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 200,000 | $7.16M | 2.7% | +200,000 | New | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 30,000 | $7.27M | 2.7% | +10,000+50.0% | Added | History |
| QUREuniQure N.V. | SHS | 375,000 | $7.55M | 2.9% | +375,000 | New | History |
| JNJJohnson & Johnson | Stock | 50,000 | $7.75M | 2.9% | +50,000 | New | History |
| RVNCRevance Therapeutics, Inc. | COM | 250,000 | $8.05M | 3.0% | −50,000−16.7% | Reduced | History |
| PFEPfizer Inc | Stock | 200,000 | $8.16M | 3.1% | +200,000 | New | History |
| SRPTSarepta Therapeutics, Inc. | COM | 60,000 | $8.27M | 3.1% | +5,000+9.1% | Added | History |
| CTICCti Biopharma Corp | COM | 2,000,000 | $8.40M | 3.2% | +150,000+8.1% | Added | History |
| PCVXVaxcyte, Inc. | COM | 225,000 | $8.43M | 3.2% | +65,000+40.6% | Added | History |
| VKTXViking Therapeutics, Inc. | COM | 600,000 | $9.99M | 3.8% | +300,000+100.0% | Added | History |
| AKROAkero Therapeutics, Inc. | COM | 275,000 | $10.5M | 4.0% | +190,000+223.5% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 164,620 | $10.9M | 4.1% | −135,380−45.1% | Reduced | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 110,000 | $11.8M | 4.5% | −20,000−15.4% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 225,000 | $13.9M | 5.3% | −10,000−4.3% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 475,000 | $13.9M | 5.3% | +125,000+35.7% | Added | History |
| TGTXTG Therapeutics, Inc. | COM | 1,100,000 | $16.5M | 6.3% | +1,100,000 | New | History |
Options (6)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| RETAReata Pharmaceuticals Inc | CL A | – | $27.3M |
| State Street SPDR S&P Biotech ETF78464A870 | ETF | – | $22.9M |
| SRPTSarepta Therapeutics, Inc. | COM | – | $17.2M |
| APLSApellis Pharmaceuticals, Inc. | COM | – | $3.42M |
| ALTAltimmune, Inc. | COM NEW | – | $1.69M |
| ETNB89bio, Inc. | COM | – | $1.52M |
Sold out since Q4 2022 (7)
Positions held at the end of Q4 2022 that are gone from this filing.
| Security | Class | Shares in Q4 2022 | Value in Q4 2022 | % of portfolio in Q4 2022 | History |
|---|---|---|---|---|---|
| Invesco QQQ Trust Series I46090E103 | ETF | 50,000 | $13.3M | 5.7% | – |
| SGENSeagen Inc. | COM | 85,000 | $10.9M | 4.7% | History |
| PRVBProvention Bio, Inc. | COM | 400,000 | $4.23M | 1.8% | History |
| RAPTRAPT Therapeutics, Inc. | COM | 125,000 | $2.48M | 1.1% | History |
| BPMCBlueprint Medicines Corp | COM | 20,000 | $876.0K | 0.4% | History |
| DSGNDesign Therapeutics, Inc. | COM | 82,853 | $850.0K | 0.4% | History |
| SYRESpyre Therapeutics, Inc. | COM | 800,000 | $360.0K | 0.2% | History |